Although several studies on checkpoint inhibition through the PD-L1/PD-1-axis or monotherapies with trastuzumab in the pancreatic cancer setting are ongoing, these approaches have so far failed to elicit efficacy (33, 34), which is in line with our current in vitro data. Here, CD274 is linked to pancreatic neoplasm.